Safety and efficacy of a feed additive consisting of endo‐1,4‐β‐xylanase (Komagataella phaffii ATCC PTA‐127053) (Xygest™ HT) for all porcine species (Kemin Europa N.V.) Authors: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Giovanna Martelli, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Katerina Theodoridou, Montserrat Anguita, Matteo L. Innocenti, Jordi Ortuño Published: 2026 ABSTRACT AbstractFollowing a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of the additive containing endo‐1,4‐β‐xylanase produced with Komagataella phaffii ATCC PTA‐127053 as a zootechnical feed additive (functional group: digestibility enhancers) for all porcine species. The additive is intended to be used in feed for all porcine species at a recommended minimum level of 90,000 U/kg complete feed for porcine species for fattening and reared for reproduction, and 45,000 U/kg complete feed for reproductive porcine species. In a previous FEEDAP opinion, the production strain was considered suitable for the qualified presumption of safety (QPS) approach to safety assessment and the additive was considered safe for the consumers and for the environment; the Panel also concluded that the additive is not irritant to eyes and skin, but it is considered a dermal and respiratory sensitiser. The FEEDAP Panel could not conclude on the safety for gestating sows and on the efficacy for all porcine species. Based on the no observed adverse effect level (NOAEL) derived from a sub‐chronic oral toxicity study conducted in rats, the Panel concluded that the additive is safe at the proposed minimum levels for all porcine species. Due to the lack of sufficient data, the Panel was not in a position to conclude on the efficacy for all porcine species. INTRODUCTION Background and Terms of Reference Regulation (EC) No 1831/2003 establishes the rules governing the Union authorisation of additives for use in animal nutrition; in particular, Article 9 defines the terms of the authorisation by the Commission. The applicant is seeking a Union authorisation of the feed additive described in Table 1. TABLE 1Description of the additive.Category of additivesZootechnical additivesFunctional groups of additivesDigestibility enhancersDescriptionEndo‐1,4‐β‐xylanase produced with Komagataella phaffii ATCC PTA‐127053Target animal categoryAll Suidae 1 ApplicantKemin Europa N.VType of requestNew opinion – Request for scientific opinion pursuant to Article 29(1)(a) of Regulation (EC) No 178/2002 Description of the additive. On 15.01.2024, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), in its opinion on the safety and efficacy of a feed additive consisting of endo‐1,4‐β‐xylanase produced with Komagataella phaffii ATCC PTA‐127053 as a zootechnical additive for all Suidae, could not conclude on the safety of the additive for gestating sows and on the efficacy of the additive for all Suidae. The European Commission gave the possibility to the applicant to submit supplementary information and data to complete the assessment and to allow a revision of the EFSA opinion. The supplementary information and data have been transmitted by the applicant using the E‐Submission Food Chain Platform (application number FEED‐2024‐33070). In view of the above and in accordance with Article 29(1)(a) of Regulation (EC) No 178/2002, the European Commission requests EFSA to deliver a new scientific opinion on a feed additive consisting of endo‐1,4‐β‐xylanase produced with K. phaffii ATCC PTA‐127053 as a zootechnical additive for all Suidae under the conditions of Regulation (EC) No 1831/2003, based on the supplementary information and data submitted by the applicant. DATA AND METHODOLOGIES Data The present assessment is based on data submitted by the applicant in the form of supplementary information 2 to a previous application on the same product. 3 The dossier was received on 18/12/2024 and the general information and supporting documentation are available on Open.EFSA at https://open.efsa.europa.eu/questions/EFSA‐Q‐2024‐00716. Methodologies The approach followed by the FEEDAP Panel to assess the safety and the efficacy of endo‐1,4‐β‐xylanase produced with K. phaffii ATCC PTA‐127053 (Xygest™ HT) is in line with the principles laid down in Regulation (EC) No 429/2008 4 and the relevant guidance documents: Guidance on the assessment of the safety of feed additives for the target species (EFSA FEEDAP Panel, 2017), Guidance on the assessment of the efficacy of feed additives (EFSA FEEDAP Panel, 2024a). ASSESSMENT The feed additive under assessment consists of endo‐1,4‐β‐xylanase produced by K. phaffii and is intended for use as a zootechnical additive (functional group: digestibility enhancers) for all porcine species at a recommended use level of 90,000 U 5 /kg complete feed for piglets (suckling and weaned), pigs for fattening and minor porcine species (suckling piglets, weaned piglets and pigs for fattening), and of 45,000 U/kg complete feed for sows for reproduction and minor porcine species for reproduction. Hereafter, the additive is referred to as Xygest™ HT, its trade name. The additive was characterised in a previous opinion, and the production strain was considered suitable for the qualified presumption of safety (QPS) approach to safety assessment (EFSA FEEDAP Panel, 2024b). The Panel concluded that the use of the additive in animal nutrition under the proposed conditions of use does not pose any safety concern for the consumers and for the environment. The additive was considered not irritant to skin or eyes, but a dermal and respiratory sensitiser. The Panel concluded that the additive is safe at 90,000 U/kg feed for all growing porcine species and at 45,000 U/kg feed for all lactating porcine species. However, the Panel could not conclude on the safety of the additive for gestating sows. In the absence of sufficient data, the FEEDAP Panel could not conclude on the efficacy of Xygest™ HT for all porcine species. In the current dossier, the applicant submitted one sub‐chronic oral toxicity study in rats to support the safety for the target species, and a series of trials in weaned piglets and pigs for fattening to support the efficacy. The new information is described below. Safety for the target species In the previous assessment, based on a tolerance trial in weaned piglets and one in sows, Xygest™ HT was considered safe at the recommended use level for piglets (suckling and weaned) and pigs for fattening from all porcine species, and all lactating porcine species. However, no conclusions could be drawn on the safety of the additive for gestating sows (EFSA FEEDAP Panel, 2024b). No new tolerance studies in relevant target species were submitted. In order to support the safety of the additive for the target species, the applicant submitted a sub‐chronic oral toxicity study conducted with rats. 6 The study was conducted according to the OECD Test Guideline (TG) 408 and claimed to follow the principles of good laboratory practices (GLP). In this study, 20 Sprague Dawley rats (10 males and 10 females per group) were administered oral doses of Xygest™ HT at concentrations of 0 (vehicle control), 250, 500 and 1000 mg/kg body weight, respectively, for 90 days. The study included two recovery groups consisting of five animals/sex per group (one vehicle control group and one group receiving 1000 mg/kg body weight) which were necropsied after a non‐exposure period of 28 days. The study did not show any test item‐related changes in clinical signs, mortality, body weight, feed consumption, organ weight, sensory and function tests, ophthalmoscopic examination, vaginal smear, haematology, urinalyses, biochemistry parameters and gross or microscopic pathology. A significant dose‐dependent increase in serum triiodothyronine (T3), thyroxine (T4) and thyroid‐stimulating hormone (TSH) was observed. However, this finding is considered non‐adverse as there was no correlation with histopathology, organ weight changes, body weight changes or any clinical sign indicative of thyroid dysfunction. Based on these observations it can be concluded that the no observed adverse effect level (NOAEL) in Sprague Dawley rats after repeated oral dosing of Xygest™ HT for 90 days is 1000 mg/kg body weight, the highest dose tested (corresponding to 3,708,396 U/kg body weight and day). The NOAEL identified (3,708,396 U/kg body weight per day) was used to calculate the maximum safe level in all relevant porcine categories in accordance with the procedure described in the Guidance on the safety for the target species (EFSA FEEDAP Panel, 2017). The applicant provided different values of feed intake and body weight for gestating sows than those listed in the guidance for gestating sows 7 and calculated the maximum safe level in feed in accordance with the above‐mentioned procedure; the results are shown in Table 2. TABLE 2Maximum safe level of endo‐1,4‐β‐xylanase produced by Komagataella phaffii ATCC PTA‐127053 in the feed of the major target species.Animal categoryDefault values for daily feed intake (g DM per kg bw)Maximum safe level in feed (U/kg complete feed)Piglet44741,679Pig for fattening37890,015Sow lactating301,081,616Sow gestating 1 301,081,616Sow gestating 2 201,631,694 1 Calculated using the default values for daily feed intake assigned by EFSA for lactating sows. 2 Calculated with the assumption that gestating sows eat less than lactating sows (3.5 kg/day). Maximum safe level of endo‐1,4‐β‐xylanase produced by Komagataella phaffii ATCC PTA‐127053 in the feed of the major target species. Calculated using the default values for daily feed intake assigned by EFSA for lactating sows. Calculated with the assumption that gestating sows eat less than lactating sows (3.5 kg/day). Based on the maximum safe levels calculated above and the results of the tolerance trials assessed in the previous Opinion, the Panel concludes that the additive is safe for all porcine species and categories at the proposed conditions of use. Efficacy In the previous opinion, the FEEDAP Panel evaluated three trials in weaned piglets and four in sows to support the efficacy of the additive (EFSA FEEDAP Panel, 2024b). Of the three long‐term trials with weaned piglets, two were not considered further in the assessment due to limitations in the study design. The remaining trial showed improved zootechnical performance at the proposed minimum use level (90,000 U/kg feed). Of the four trials in sows, two showed positive effects of the additive on the energy utilisation of the diets during the lactation period at 45,000 U/kg, but no evidence of efficacy was shown in gestating sows. No new data regarding the efficacy of the additive on gestating sows was provided. The applicant has now submitted one trial in weaned piglets and three in pigs for fattening aiming at demonstrating the effect of the additive on zootechnical performance and/or the energy utilisation of the diets. However, the trial in weaned piglets 8 and one of the trials in pigs for fattening 9 showed poor health performance of the animals, as indicated by high morbidity rates, ■■■■■ animals treated with antibiotics, and suboptimal mortality and culling rates. In the trial in weaned piglets, low productive performance was also observed, with an average daily gain ■■■■■ below European standards for this production phase). Overall, these studies were not considered further as evidence of efficacy. The other two trials submitted in pigs for fattening were a combined trial evaluating the effects on the zootechnical performance of the animals and on energy utilisation, and a short‐term balance trial focused on the effects of the additive on the energy utilisation of the diet. TABLE 3Trial design and use level of the efficacy trials performed in pigs for fattening.TrialTotal n° of animals (animals × replicate)replicates × treatmentBreed sexDurationComposition feed (form)Groups (U/kg feed)IntendedAnalysed 1 ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ 2 ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ Trial design and use level of the efficacy trials performed in pigs for fattening. ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ In the long‐term trial, 10 ■■■■■ pigs (■■■■■) were ■■■■■ distributed in floor‐pens, which were randomly allocated to the experimental groups. The basal diet was either not supplemented (control) or supplemented with Xygest™ HT ■■■■■ (enzymatic activity in feed confirmed analytically; see Table 3). The experimental feeds were offered ad libitum ■■■■■ until slaughter weight. The mortality and health status of the animals were checked ■■■■■, and the most likely cause of death registered. The animals were weighed ■■■■■, and the feed intake recorded for the corresponding periods. The average daily feed intake, average daily gain and feed‐to‐gain ratio were calculated for the overall period. The performance data were corrected for mortality. ■■■■■, faecal samples were taken from each pen to estimate the apparent total tract digestibility of the dry matter and energy. The Panel notes that urine samples were not taken, which prevented estimation of the metabolisable energy of the diets. Therefore, the analysis of the energy digestibility was not considered for the evaluation of the efficacy of the additive. The experimental data were statistically analysed ■■■■■, with the pen as experimental unit and diet ■■■■■ as fixed effects. When differences were detected, group means were compared ■■■■■. Mortality data were statistically analysed ■■■■■. The significance level was set at 0.05. (Table 4). TABLE 4Effects of Xygest™ HT on the zootechnical performance of pigs for fattening in trial 1.Groups (U/kg feed)Daily feed intake (kg)Final body weight (kg)Average daily weight gain (kg)Feed‐to‐gain ratioMortality and culling (%)■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■a,b: Mean values within a column with a different superscript are significantly different P < 0.05. Effects of Xygest™ HT on the zootechnical performance of pigs for fattening in trial 1. a,b: Mean values within a column with a different superscript are significantly different P < 0.05. The pigs receiving the additive at any level showed no improvement in the zootechnical performance compared to the control. In the short‐term balance trial, 11 ■■■■■ pigs ■■■■■ were distributed to individual metabolic cages, randomly allocated to three experimental groups. The basal diet was either not supplemented (control) or supplemented with Xygest™ HT ■■■■■ (enzymatic activity in feed confirmed analytically; see Table 3). The animals were adapted to the experimental diets and husbandry conditions from days ■■■■■ of the trial; from days ■■■■■, faeces and urine ■■■■■ were sampled ■■■■■. ■■■■■ Feed, faeces and urine samples were analysed for the dry matter and gross energy contents. The zootechnical performance of the animals was monitored during the whole period. The experimental data were statistically analysed ■■■■■ with the animal as experimental unit, diet as fixed effect ■■■■■. The significance level was set at 0.05. No animal died or was culled during the trial. No differences were observed in the zootechnical performance parameters between groups (data not shown). The inclusion of Xygest™ HT showed no improvement of the metabolisable energy of the diets at any level (Table 5). TABLE 5Effects of Xygest™ HT on the dry matter and energy utilisation of pigs for fattening in trial 2.Groups (U/kg feed)ATTD of dry matter (%)ATTD of gross energy (%)Metabolisable energy utilisation (%)■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■Abbreviation: ATTD, apparent total tract digestibility. Effects of Xygest™ HT on the dry matter and energy utilisation of pigs for fattening in trial 2. Abbreviation: ATTD, apparent total tract digestibility. Conclusion on efficacy Based on the data provided in this and previous application, only one trial in weaned piglets and two in lactating sows supported the efficacy of Xygest™ HT at the proposed conditions of use. Therefore, due to the lack of sufficient data, the Panel is not in a position to conclude on the efficacy of the additive in all porcine species. At least one additional trial in pigs for fattening and another in gestating sows showing positive effects on key parameters would be needed to support the efficacy of the additive in all porcine species. Post‐market monitoring The FEEDAP Panel considers that there is no need for specific requirements for a post‐market monitoring plan other than those established in the Feed Hygiene Regulation 12 and Good Manufacturing Practice. CONCLUSIONS The use of Xygest™ HT is considered safe for all porcine species at the proposed conditions of use. Due to the lack of sufficient data, the Panel is not in a position to conclude on the efficacy of the additive in all porcine species. ABBREVIATIONS American Type Culture Collection apparent total tract digestibility body weight dry matter EFSA Scientific Panel on Additives and Products or Substances used in Animal Feed good laboratory practices no observed adverse effect level Organisation for Economic Co‐operation and Development qualified presumption of safety triiodothyronine thyroxine thyroid‐stimulating hormone REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2024‐00716 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Giovanna Martelli, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Ilen Röhe, Katerina Theodoridou. LEGAL NOTICE The published scientific output includes information items that have been redacted, in accordance with the confidentiality requests submitted by the applicant, pending a decision thereon by EFSA. Redactions may be subject to review once a decision on such confidentiality requests is taken by EFSA.